HCPCS Codes Similar to G9845

HCPCS Codes Similar to “G9845” Code.
Patient received anti-egfr monoclonal antibody therapy

G9839 Anti-egfr monoclonal antibody therapy Code added date: 20170101 Code effective date: 20170101 TXT \| PDF \| XML \| JSON	G9844 Patient did not receive anti-egfr monoclonal antibody therapy Code added date: 20170101 Code effective date: 20170101 TXT \| PDF \| XML \| JSON
M0235 Intravenous infusion, monoclonal antibody products with an indication for post-exposure prophylaxis or treatment of covid-19, for hospitalized adults and/or pediatric patients who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ecmo) only, includes infusion and post administration monitoring, not otherwise classified, first dose Code added date: 20251001 Code effective date: 20251001 TXT \| PDF \| XML \| JSON	M0236 Intravenous infusion, monoclonal antibody products with an indication for post-exposure prophylaxis or treatment of covid-19, for hospitalized adults and/or pediatric patients who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ecmo) only, includes infusion and post administration monitoring, not otherwise classified, second dose Code added date: 20251001 Code effective date: 20251001 TXT \| PDF \| XML \| JSON
Q0235 Injection, monoclonal antibody products with an indication for post-exposure prophylaxis or treatment of covid-19, for hospitalized adults and/or pediatric patients who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ecmo) only, not otherwise classified, 1 mg Code added date: 20251001 Code effective date: 20251001 TXT \| PDF \| XML \| JSON	S9562 Home injectable therapy, palivizumab or other monoclonal antibody for rsv, including administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diem Code added date: 20030101 Code effective date: 20230401 TXT \| PDF \| XML \| JSON
G9840 Ras (kras and nras) gene mutation testing performed before initiation of anti-egfr moab Code added date: 20170101 Code effective date: 20180101 TXT \| PDF \| XML \| JSON	G9841 Ras (kras and nras) gene mutation testing not performed before initiation of anti-egfr moab Code added date: 20170101 Code effective date: 20180101 TXT \| PDF \| XML \| JSON
M1412 Patients with metastatic nsclc with epidermal growth factor receptor (egfr) mutations, alk genomic tumor aberrations, or other targetable genomic abnormalities with approved first-line targeted therapy, such as nsclc with ros1 rearrangement, braf v600e mutation, ntrk 1/2/3 gene fusion, met ex14 skipping mutation, and ret rearrangement Code added date: 20250101 Code effective date: 20250101 TXT \| PDF \| XML \| JSON	M1228 Patient, who has a reactive hcv antibody test, and has a follow up hcv viral test that detected hcv viremia, has hcv treatment initiated within 3 months of the reactive hcv antibody test Code added date: 20240101 Code effective date: 20240101 TXT \| PDF \| XML \| JSON
M1229 Patient, who has a reactive hcv antibody test, and has a follow up hcv viral test that detected hcv viremia, is referred within 1 month of the reactive hcv antibody test to a clinician who treats hcv infection Code added date: 20240101 Code effective date: 20240101 TXT \| PDF \| XML \| JSON	M1230 Patient has a reactive hcv antibody test and does not have a follow up hcv viral test, or patient has a reactive hcv antibody test and has a follow up hcv viral test that detects hcv viremia and is not referred to a clinician who treats hcv infection within 1 month and does not have hcv treatment initiated within 3 months of the reactive hcv antibody test, reason not given Code added date: 20240101 Code effective date: 20240101 TXT \| PDF \| XML \| JSON
M1231 Patient receives hcv antibody test with nonreactive result Code added date: 20240101 Code effective date: 20240101 TXT \| PDF \| XML \| JSON	M1232 Patient receives hcv antibody test with reactive result Code added date: 20240101 Code effective date: 20240101 TXT \| PDF \| XML \| JSON